A Critical Analysis of Pituitary Tumor Shrinkage during Primary Medical Therapy in Acromegaly
- 1 July 2005
- journal article
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 90 (7) , 4405-4410
Abstract
Context: Somatostatin analogs have been successfully used to treat patients with GH-secreting pituitary adenomas because they are safe, effective, and usually well tolerated. The results of studies evaluating acromegaly treatment with the somatostatin receptor ligands (SRLs), octreotide and lanreotide, have supported the use of these agents for primary medical therapy before or as an alternative to traditional interventions of surgery and radiotherapy in selected cases. Evidence Acquisition: We therefore undertook a systematic literature overview to characterize the results of studies involving primary therapy with somatostatin analogs and their effects on pituitary tumor size. Because most studies in which pituitary tumor shrinkage has been assessed involve uncontrolled, open-label, prospective trials or retrospective case series, the lack of a control arm does not permit pooling of data in a metaanalytic fashion to determine tumor size reduction. Therefore, this systematic review was designed to document and stratify data by study design, summarize therapeutic regimens and patient characteristics, assess the percentage of patients showing changes in tumor size, and calculate the weighted average effect on size reduction. Evidence Synthesis: Overall, for patients who experience significant shrinkage, an approximately 50% decrease in pituitary mass is achieved when a somatostatin analog is used exclusively or before surgery or radiotherapy. Fourteen studies (n = 424) provided a definition of significant tumor shrinkage, and the results showed that 36.6% (weighted mean percentage) of patients receiving primary SRL therapy for acromegaly experienced a significant reduction in tumor size. The weighted mean percent reduction in tumor size was 19.4% for those studies in which all patients received SRLs and change in tumor size was reported for all patients. Conclusions: Clinical implications are discussed for patients in whom tumor size control with SRLs is an important objective, typically those who have failed surgery or are being treated with primary medical therapy with large tumors.Keywords
This publication has 30 references indexed in Scilit:
- Lanreotide 60 mg, a New Long-Acting Formulation: Effectiveness in the Chronic Treatment of AcromegalyThe Journal of Clinical Endocrinology & Metabolism, 2003
- Preoperative lanreotide treatment for GH-secreting pituitary adenomas: effect on tumour volume and predictive factors of significant tumour shrinkageClinical Endocrinology, 2003
- Primary Medical Therapy for Acromegaly: An Open, Prospective, Multicenter Study of the Effects of Subcutaneous and Intramuscular Slow-Release Octreotide on Growth Hormone, Insulin-Like Growth Factor-I, and Tumor SizeThe Journal of Clinical Endocrinology & Metabolism, 2002
- Long‐term effects of lanreotide SR and octreotide LAR® on tumour shrinkage and GH hypersecretion in patients with previously untreated acromegalyClinical Endocrinology, 2002
- Effects of preoperative octreotide treatment on different subtypes of 90 GH-secreting pituitary adenomas and outcome in one surgical centreEuropean Journal of Endocrinology, 2001
- Does Octreotide Treatment Improve the Surgical Results of Macro-Adenomas in Acromegaly? A Randomized StudyActa Neurochirurgica, 1999
- Preoperative Short-term Administration of Octreotide for Facilitating Transsphenoidal Removal of Invasive Growth Hormone-secreting MacroadenomasNeurologia medico-chirurgica, 1999
- Preoperative Treatment of Growth Hormone-Producing Pituitary Adenoma with Continuous Subcutaneous Infusion of Octreotide.Endocrine Journal, 1998
- Effect of Octreotide Pretreatment on Surgical Outcome in AcromegalyThe Journal of Clinical Endocrinology & Metabolism, 1997
- Presurgical octreotide: Treatment in acromegalyMetabolism, 1996